Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olopatadine - Kyowa Hakko Kirin

Drug Profile

Olopatadine - Kyowa Hakko Kirin

Alternative Names: AL-4943A; Allelock; ALO 4943A; KW-4679; Olopatadine hydrochloride; Opatanol; Pataday; Patanase; Patanol; Pazeo

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Alcon; Kyowa Hakko Kirin
  • Class Antiallergics; Antihistamines; Dibenzoxepins; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Pruritus; Rhinitis; Seasonal allergic rhinitis; Urticaria
  • Discontinued Asthma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2015 Alcon Research completes phase III trial in Allergic conjunctivitis in China (NCT02322216)
  • 30 Jan 2015 Registered for Allergic conjunctivitis in USA (Ophthalmic, 0.7%)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top